TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
Late Wednesday FDA approved Varubi rolapitant IV (injection type) from Tesaro Inc. (NASDAQ:TSRO) in combination with other antiemetic agents in adults to prevent delayed chemotherapy-induced nausea and vomiting (CINV). The company already markets an oral version of the tachykinin receptor (TACR1; NK1R) antagonist. The company has exclusive, worldwide rights to rolapitant from Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK).
VARUBIの注射薬ver、承認されたみたいだねｗ
TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
Late Wednesday FDA approved Varubi rolapitant IV (injection type) from Tesaro Inc. (NASDAQ:TSRO) in combination with other antiemetic agents in adults to prevent delayed chemotherapy-induced nausea and vomiting (CINV). The company already markets an oral version of the tachykinin receptor (TACR1; NK1R) antagonist. The company has exclusive, worldwide rights to rolapitant from Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK).